TC
REVBW icon

T3 Companies’s Revelation Biosciences Warrant REVBW Stock Holding History

T3 Companies’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
198,090
– – ﹤0.01% 232
2025
Q4 		$1.58K Buy
+198,090
New +$2.14K ﹤0.01% 187

Other funds holding REVBW

LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.18B AUM 26.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SIA
Soltis Investment Advisors St. George, Utah $1.59B AUM 23.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
QWM
Quaker Wealth Management Moorestown, New Jersey $320M AUM 13.7% 1-Year Est. Return

T3 Companies's REVBW Position: Q1 2026 in Review

T3 Companies held its Revelation Biosciences Warrant (REVBW) position steady in Q1 2026 at 198,090 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #232.

T3 Companies first reported a position in REVBW in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.58K in Q4 2025. 11 funds tracked by Wall St. Rank hold REVBW as of Q1 2026.

  • T3 Companies held 198,090 shares of Revelation Biosciences Warrant worth $0 as of Q1 2026.
  • T3 Companies left its Revelation Biosciences Warrant share count unchanged in Q1 2026.
  • Revelation Biosciences Warrant made up ﹤0.01% of T3 Companies's portfolio in Q1 2026, its #232 holding.
  • T3 Companies first reported a position in Revelation Biosciences Warrant in Q4 2025 and has held it in 2 quarters since.
  • T3 Companies's Revelation Biosciences Warrant position peaked at $1.58K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.